In order to increase the layout of the traditional Chinese medicine industry, many pharmaceutical companies plan to acquire and merge!

[Pharmaceutical Network Industry News] Traditional Chinese medicine is a treasure of Chinese civilization, and has obvious advantages in disease prevention, treatment and rehabilitatio.
In recent years, with the aging of the population, the upgrading of consumption, and the blessing of national policy dividends, the Chinese medicine industry has developed rapidly, and the future market prospects are broa.
The industry predicts that the size of the Chinese medicine market will exceed one trillion yuan by 2022, and will reach 1375 trillion yuan in 2024, which also attracts more companies to deploy Chinese medicine and makes companies on the track full of confidence in future developmen.
Recently, Wanbangde said in an investor survey that in the future, the company's pharmaceutical manufacturing sector will focus on the traditional Chinese medicine industry, jointly develop traditional Chinese medicine products, sort out the existing 24 traditional Chinese medicine products and carry out secondary research and development, and will not rule out acquisitions and mergers to enrich traditional Chinese medicin.
product structur.
According to the data, Wanbangde is mainly engaged in the pharmaceutical manufacturing industry and medical device busines.
The pharmaceutical manufacturing business mainly includes the research and development, production and sales of modern traditional Chinese medicine, chemical raw materials and chemical preparation.
The products involve cardiovascular and cerebrovascular, nervous system, respiratory syste.
and digestive system disease.
The author noticed that Wanbangde recently planned to increase the layout of the traditional Chinese medicine industry through the acquisition of traditional Chinese medicine companie.
Wanbangde announced on the evening of July 25 that it intends to acquire a total of 238 million shares of Hong Kong-listed company Consun Pharmaceutical by paying cash, accounting for 250% of its total share capita.
According to the data, Kangchen Pharmaceutical is a modern pharmaceutical company engaged in the research, development, production and sales of proprietary Chinese medicines and medical imaging contrast agent.
It has strong advantages in the field of urinary system, especially in the field of traditional Chinese medicine in nephrolog.
In 2020 and 2021, Kangchen Pharmaceutical's revenue will be 753 billion yuan and 045 billion yuan respectively; the net profit attributable to the parent will be 499 million yuan and 590 million yuan respectivel.
Regarding this acquisition, Wanbangde said that if it can be successfully completed, Wanbangde, as the largest shareholder, can promote in-depth cooperation in the field of traditional Chinese medicine and promote the sustainable development of the company's core business of traditional Chinese medicine healt.
Judging from Wanbang's performance, from 2020 to 2021, Wanbang's pharmaceutical manufacturing business revenue increased slightly from 985 million yuan to 999 million yuan, an increase of only 51.
In this regard, the industry believes that the company's layout of the traditional Chinese medicine industry through mergers and acquisitions may bring growth points to its performanc.
In addition to Wanbangde, there are many pharmaceutical companies that plan to acquire and deploy traditional Chinese medicin.
For example, on August 9, Dorui Medicine announced that the company plans to acquire 40% of the shares of Bozhou Tianji held by Hubei Tianj.
For the purpose of this acquisition, the company stated that it is conducive to accelerating the improvement of the company's traditional Chinese medicine industry layout and further enhancing the company's profitabilit.
Earlier in November 2021, in order to deepen the layout of the traditional Chinese medicine industry, Jingxin Pharmaceutical planned to acquire 99% of Shaxi Pharmaceutical held by Yuanjin Health and 1% of Shaxi Pharmaceutical held by Jingxin Holdings for 205 million yuan; It is proposed to acquire a 6% stake in Hu Qingyutang held by Yuanjin Health for 218 million yua.
The company said that through this acquisition, the company can effectively integrate the resources of the company's traditional Chinese medicine industry, comprehensively utilize the advantages of brand, culture and channels, further expand the layout of the traditional Chinese medicine industry, and realize the positive development of the existing traditional Chinese medicine busines.
It can be seen that with the support of favorable policies, the considerable market prospects of the traditional Chinese medicine industry are being optimistic about the pharmaceutical companie.
However, returning to the long-term development of enterprises, traditional Chinese medicine enterprises also need to focus on innovative research and development in order to go furthe.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.